This website uses functional cookies, including analytical cookies. The obtained statistical data cannot be traced back to individual users. Additionally, you can choose to accept or refuse consent to use marketing cookies. If you decline these additional cookies or refrain from making a choice, only functional cookies will be set. See our cookie policy for more information.
Prof. Vareska van der Vrande, Dr Patricia Klopf, and the Research Software Engineering and Consulting (RSEC) team at RSM are listed as funders for this article on pharmaceutical firms' resource allocation decision toward lobbying and other non-market activities, and their their new drug launches.
The research is published in an Elsevier publication Research Policy, 2024;53(2).
Information for this cutting came from https://www.newsrx.com/NewsRxWebsite/